Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

10.1016/j.jacc.2021.04.079

Saved in:

Bibliographic Details
Main Authors:	Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators.
Other Authors:	DUKE-NUS MEDICAL SCHOOL
Format:	Article
Published:	Elsevier Inc. 2022
Subjects:	chronic kidney disease clinical trial finerenone mineralocorticoid receptor antagonist new-onset atrial fibrillation type 2 diabetes
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/232604
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Description
Summary:	10.1016/j.jacc.2021.04.079